Xbrane Inching Closer To Cimzia Biosimilar Trials With Batch Production
Swedish Firm Eyeing Completion Of Duties By Mid-2025; Then Handing To Biogen
Executive Summary
Sweden’s Xbrane Biopharma has delivered updates for two of its more long-term projects, including a proposed biosimilar to Bristol Myers Squibb’s Opdivo for which it is actively seeking a partner.